PMC:7205724 / 17446-18542
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
599 | 49-54 | Species | denotes | human | Tax:9606 |
613 | 138-143 | Species | denotes | human | Tax:9606 |
614 | 328-342 | Species | denotes | Parvovirus B19 | Tax:10798 |
615 | 389-410 | Species | denotes | Clostridium difficile | Tax:1496 |
616 | 423-442 | Species | denotes | Mycobacterium avium | Tax:1764 |
617 | 444-470 | Species | denotes | Mycobacterium tuberculosis | Tax:1773 |
618 | 199-219 | Disease | denotes | autoimmune disorders | MESH:D001327 |
619 | 223-252 | Disease | denotes | primary antibody deficiencies | MESH:D000081207 |
620 | 320-326 | Disease | denotes | sepsis | MESH:D018805 |
621 | 343-352 | Disease | denotes | infection | MESH:D007239 |
622 | 364-382 | Disease | denotes | virus encephalitis | MESH:D004660 |
623 | 411-421 | Disease | denotes | infections | MESH:D007239 |
624 | 476-495 | Disease | denotes | Nocardia infections | MESH:D009617 |
625 | 511-521 | Disease | denotes | infections | MESH:D007239 |
633 | 622-631 | Species | denotes | 2019-nCoV | Tax:2697049 |
634 | 856-864 | Species | denotes | patients | Tax:9606 |
635 | 568-576 | Species | denotes | patients | Tax:9606 |
636 | 661-670 | Disease | denotes | infection | MESH:D007239 |
637 | 870-877 | Disease | denotes | COVID19 | MESH:C000657245 |
638 | 996-1003 | Disease | denotes | COVID19 | MESH:C000657245 |
639 | 1087-1095 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T135 | 231-239 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T136 | 384-387 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T137 | 695-700 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
T138 | 777-780 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T139 | 785-788 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T140 | 920-934 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T20 | 695-700 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T123 | 199-219 | Disease | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/MONDO_0007179 |
T124 | 223-252 | Disease | denotes | primary antibody deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
T125 | 343-352 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T126 | 364-382 | Disease | denotes | virus encephalitis | http://purl.obolibrary.org/obo/MONDO_0006009 |
T127 | 370-382 | Disease | denotes | encephalitis | http://purl.obolibrary.org/obo/MONDO_0019956 |
T128 | 389-421 | Disease | denotes | Clostridium difficile infections | http://purl.obolibrary.org/obo/MONDO_0000705 |
T129 | 458-470 | Disease | denotes | tuberculosis | http://purl.obolibrary.org/obo/MONDO_0018076 |
T130 | 476-495 | Disease | denotes | Nocardia infections | http://purl.obolibrary.org/obo/MONDO_0017776 |
T131 | 511-524 | Disease | denotes | infections in | http://purl.obolibrary.org/obo/MONDO_0005550 |
T132 | 525-556 | Disease | denotes | primary antibodies deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
T133 | 661-670 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T134 | 870-877 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T135 | 996-1003 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T136 | 1087-1095 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T217 | 33-34 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T218 | 49-54 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T219 | 125-126 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T220 | 138-143 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T221 | 265-268 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T222 | 339-342 | http://purl.obolibrary.org/obo/CLO_0001798 | denotes | B19 |
T223 | 364-369 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T224 | 608-610 | http://purl.obolibrary.org/obo/CLO_0008192 | denotes | NP |
T225 | 678-680 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
T226 | 808-810 | http://purl.obolibrary.org/obo/CLO_0008192 | denotes | NP |
T227 | 814-816 | http://purl.obolibrary.org/obo/CLO_0001527 | denotes | 94 |
T228 | 846-848 | http://purl.obolibrary.org/obo/CLO_0001527 | denotes | 94 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T156 | 608-610 | Chemical | denotes | NP | http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425 |
T159 | 808-810 | Chemical | denotes | NP | http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T13 | 920-934 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T70 | 144-152 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | diseases |
T71 | 210-219 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
T72 | 320-326 | http://purl.obolibrary.org/obo/IDO_0000636 | denotes | sepsis |
T73 | 343-352 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infection |
T74 | 364-369 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T75 | 411-421 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections |
T76 | 485-495 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections |
T77 | 511-524 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections in |
T78 | 661-670 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infection |
T79 | 741-748 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptom |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T165 | 49-54 | Species | denotes | human | NCBItxid:9606 |
T166 | 138-143 | Species | denotes | human | NCBItxid:9606 |
T167 | 320-326 | Species | denotes | sepsis | NCBItxid:137507 |
T168 | 328-342 | Species | denotes | Parvovirus B19 | NCBItxid:10798 |
T169 | 354-369 | Species | denotes | West Nile virus | NCBItxid:11082 |
T170 | 384-387 | Species | denotes | HIV | NCBItxid:57667|NCBItxid:35274|NCBItxid:12721|NCBItxid:11709|NCBItxid:11676 |
T175 | 389-410 | Species | denotes | Clostridium difficile | NCBItxid:1496 |
T176 | 423-442 | Species | denotes | Mycobacterium avium | NCBItxid:1764 |
T177 | 444-470 | Species | denotes | Mycobacterium tuberculosis | NCBItxid:1773 |
T178 | 476-484 | Species | denotes | Nocardia | NCBItxid:1817 |
T179 | 622-631 | Species | denotes | 2019-nCoV | NCBItxid:2697049 |
T180 | 870-877 | Species | denotes | COVID19 | NCBItxid:2697049 |
T181 | 996-1003 | Species | denotes | COVID19 | NCBItxid:2697049 |
T182 | 1087-1095 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T142 | 0-65 | Sentence | denotes | 4.2.1 Hypothesis: IVIG contains a large pool of human antibodies |
T143 | 66-253 | Sentence | denotes | IVIG is an immunomodulatory treatment currently useful for a variety of human diseases that share an idiopathic origin, ranging from autoimmune disorders to primary antibody deficiencies. |
T144 | 254-562 | Sentence | denotes | Also, IVIG has shown promising results in case of severe (such as sepsis, Parvovirus B19 infection, West Nile virus encephalitis, HIV, Clostridium difficile infections, Mycobacterium avium, Mycobacterium tuberculosis, and Nocardia infections) and recurrent infections in primary antibodies deficiencies [21]. |
T145 | 563-682 | Sentence | denotes | Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. |
T146 | 683-878 | Sentence | denotes | Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. |
T147 | 879-1004 | Sentence | denotes | Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. |
T148 | 1005-1096 | Sentence | denotes | It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19. |
LitCovid-sample-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T20 | 695-700 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
599 | 49-54 | Species | denotes | human | Tax:9606 |
613 | 138-143 | Species | denotes | human | Tax:9606 |
618 | 199-219 | Disease | denotes | autoimmune disorders | MESH:D001327 |
619 | 223-252 | Disease | denotes | primary antibody deficiencies | MESH:D000081207 |
620 | 320-326 | Disease | denotes | sepsis | MESH:D018805 |
614 | 328-342 | Species | denotes | Parvovirus B19 | Tax:10798 |
621 | 343-352 | Disease | denotes | infection | MESH:D007239 |
622 | 364-382 | Disease | denotes | virus encephalitis | MESH:D004660 |
615 | 389-410 | Species | denotes | Clostridium difficile | Tax:1496 |
623 | 411-421 | Disease | denotes | infections | MESH:D007239 |
616 | 423-442 | Species | denotes | Mycobacterium avium | Tax:1764 |
617 | 444-470 | Species | denotes | Mycobacterium tuberculosis | Tax:1773 |
624 | 476-495 | Disease | denotes | Nocardia infections | MESH:D009617 |
625 | 511-521 | Disease | denotes | infections | MESH:D007239 |
635 | 568-576 | Species | denotes | patients | Tax:9606 |
633 | 622-631 | Species | denotes | 2019-nCoV | Tax:2697049 |
636 | 661-670 | Disease | denotes | infection | MESH:D007239 |
634 | 856-864 | Species | denotes | patients | Tax:9606 |
637 | 870-877 | Disease | denotes | COVID19 | MESH:C000657245 |
638 | 996-1003 | Disease | denotes | COVID19 | MESH:C000657245 |
639 | 1087-1095 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T1970 | 339-342 | Protein | denotes | B19 | https://www.uniprot.org/uniprot/P57058 |
T1971 | 615-618 | Protein | denotes | RBD | https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022 |
T1980 | 830-833 | Protein | denotes | RBD | https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T56020 | 0-5 | CD | denotes | 4.2.1 |
T95212 | 7-17 | NN | denotes | Hypothesis |
T84611 | 17-18 | -COLON- | denotes | : |
T95417 | 19-23 | NN | denotes | IVIG |
T50853 | 24-32 | VBZ | denotes | contains |
T65863 | 33-34 | DT | denotes | a |
T68527 | 35-40 | JJ | denotes | large |
T83960 | 41-45 | NN | denotes | pool |
T57480 | 46-48 | IN | denotes | of |
T98962 | 49-54 | JJ | denotes | human |
T50450 | 55-65 | NNS | denotes | antibodies |
T12037 | 66-70 | NN | denotes | IVIG |
T52317 | 71-73 | VBZ | denotes | is |
T83276 | 74-76 | DT | denotes | an |
T47689 | 77-93 | JJ | denotes | immunomodulatory |
T32201 | 94-103 | NN | denotes | treatment |
T26744 | 104-113 | RB | denotes | currently |
T6595 | 114-120 | JJ | denotes | useful |
T61951 | 121-124 | IN | denotes | for |
T78252 | 125-126 | DT | denotes | a |
T96672 | 127-134 | NN | denotes | variety |
T75647 | 135-137 | IN | denotes | of |
T64366 | 138-143 | JJ | denotes | human |
T37666 | 144-152 | NNS | denotes | diseases |
T30663 | 153-157 | WDT | denotes | that |
T71611 | 158-163 | VBP | denotes | share |
T4369 | 164-166 | DT | denotes | an |
T95969 | 167-177 | JJ | denotes | idiopathic |
T35011 | 178-184 | NN | denotes | origin |
T94518 | 184-185 | -COMMA- | denotes | , |
T34533 | 186-193 | VBG | denotes | ranging |
T57537 | 194-198 | IN | denotes | from |
T47481 | 199-209 | JJ | denotes | autoimmune |
T10634 | 210-219 | NNS | denotes | disorders |
T96539 | 220-222 | TO | denotes | to |
T18270 | 223-230 | JJ | denotes | primary |
T92790 | 231-239 | NN | denotes | antibody |
T91348 | 240-252 | NNS | denotes | deficiencies |
T23275 | 254-258 | RB | denotes | Also |
T97483 | 258-259 | -COMMA- | denotes | , |
T12179 | 260-264 | NNP | denotes | IVIG |
T44219 | 265-268 | VBZ | denotes | has |
T10629 | 269-274 | VBN | denotes | shown |
T45168 | 275-284 | JJ | denotes | promising |
T67208 | 285-292 | NNS | denotes | results |
T77083 | 293-295 | IN | denotes | in |
T72909 | 296-300 | NN | denotes | case |
T84121 | 301-303 | IN | denotes | of |
T92712 | 304-310 | JJ | denotes | severe |
T79863 | 311-312 | -LRB- | denotes | ( |
T66824 | 312-316 | JJ | denotes | such |
T43956 | 317-319 | IN | denotes | as |
T9832 | 320-326 | NN | denotes | sepsis |
T13628 | 326-327 | -COMMA- | denotes | , |
T62406 | 328-338 | NN | denotes | Parvovirus |
T99835 | 339-342 | NN | denotes | B19 |
T14835 | 343-352 | NN | denotes | infection |
T15497 | 352-353 | -COMMA- | denotes | , |
T90831 | 354-358 | NNP | denotes | West |
T76795 | 359-363 | NNP | denotes | Nile |
T72325 | 364-369 | NN | denotes | virus |
T62294 | 370-382 | NN | denotes | encephalitis |
T79163 | 382-383 | -COMMA- | denotes | , |
T42313 | 384-387 | NN | denotes | HIV |
T73958 | 387-388 | -COMMA- | denotes | , |
T29310 | 389-400 | NNP | denotes | Clostridium |
T49447 | 401-410 | JJ | denotes | difficile |
T8038 | 411-421 | NNS | denotes | infections |
T10219 | 421-422 | -COMMA- | denotes | , |
T3443 | 423-436 | NN | denotes | Mycobacterium |
T55185 | 437-442 | NN | denotes | avium |
T2677 | 442-443 | -COMMA- | denotes | , |
T67405 | 444-457 | NN | denotes | Mycobacterium |
T65630 | 458-470 | NN | denotes | tuberculosis |
T60726 | 470-471 | -COMMA- | denotes | , |
T52785 | 472-475 | CC | denotes | and |
T44446 | 476-484 | NNP | denotes | Nocardia |
T90848 | 485-495 | NNS | denotes | infections |
T80386 | 495-496 | -RRB- | denotes | ) |
T6178 | 497-500 | CC | denotes | and |
T68317 | 501-510 | JJ | denotes | recurrent |
T17705 | 511-521 | NNS | denotes | infections |
T68999 | 522-524 | IN | denotes | in |
T18422 | 525-532 | JJ | denotes | primary |
T52471 | 533-543 | NNS | denotes | antibodies |
T62247 | 544-556 | NNS | denotes | deficiencies |
T55724 | 557-558 | -LRB- | denotes | [ |
T27007 | 558-560 | CD | denotes | 21 |
T97422 | 560-561 | -RRB- | denotes | ] |
T8813 | 563-567 | JJS | denotes | Most |
T48684 | 568-576 | NNS | denotes | patients |
T37814 | 577-584 | VBP | denotes | develop |
T41895 | 585-595 | NNS | denotes | antibodies |
T32237 | 596-603 | IN | denotes | against |
T55833 | 604-607 | DT | denotes | the |
T23466 | 608-610 | NN | denotes | NP |
T51386 | 611-614 | CC | denotes | and |
T97267 | 615-618 | NN | denotes | RBD |
T48238 | 619-621 | IN | denotes | of |
T17626 | 622-631 | NN | denotes | 2019-nCoV |
T87676 | 632-638 | IN | denotes | during |
T56543 | 639-642 | DT | denotes | the |
T74019 | 643-649 | JJ | denotes | second |
T36179 | 650-654 | NN | denotes | week |
T61939 | 655-660 | IN | denotes | after |
T53819 | 661-670 | NN | denotes | infection |
T47949 | 671-676 | NN | denotes | onset |
T10621 | 677-678 | -LRB- | denotes | [ |
T31327 | 678-680 | CD | denotes | 22 |
T53799 | 680-681 | -RRB- | denotes | ] |
T76985 | 683-691 | NN | denotes | Analysis |
T6758 | 692-694 | IN | denotes | of |
T88720 | 695-700 | NN | denotes | serum |
T73739 | 701-708 | NNS | denotes | samples |
T20072 | 709-718 | VBD | denotes | collected |
T30704 | 719-721 | CD | denotes | 14 |
T66398 | 722-724 | CC | denotes | or |
T43796 | 725-729 | JJR | denotes | more |
T64515 | 730-734 | NNS | denotes | days |
T88119 | 735-740 | IN | denotes | after |
T33297 | 741-748 | NN | denotes | symptom |
T78997 | 749-754 | NN | denotes | onset |
T69102 | 755-763 | VBD | denotes | revealed |
T51393 | 764-773 | NN | denotes | detection |
T49412 | 774-776 | IN | denotes | of |
T86080 | 777-780 | NN | denotes | IgG |
T42365 | 781-784 | CC | denotes | and |
T24248 | 785-788 | NN | denotes | IgM |
T84785 | 789-799 | NNS | denotes | antibodies |
T33598 | 800-807 | IN | denotes | against |
T65176 | 808-810 | NN | denotes | NP |
T29543 | 811-813 | IN | denotes | in |
T67075 | 814-816 | CD | denotes | 94 |
T4274 | 816-817 | NN | denotes | % |
T73088 | 818-821 | CC | denotes | and |
T74097 | 822-824 | CD | denotes | 88 |
T71868 | 824-825 | NN | denotes | % |
T54079 | 826-829 | CC | denotes | and |
T73098 | 830-833 | NN | denotes | RBD |
T69539 | 834-836 | IN | denotes | in |
T87988 | 837-840 | CD | denotes | 100 |
T78691 | 840-841 | NN | denotes | % |
T18580 | 842-845 | CC | denotes | and |
T46489 | 846-848 | CD | denotes | 94 |
T64615 | 848-849 | NN | denotes | % |
T60810 | 850-855 | IN | denotes | among |
T38563 | 856-864 | NNS | denotes | patients |
T93829 | 865-869 | IN | denotes | with |
T24980 | 870-877 | NN | denotes | COVID19 |
T89545 | 879-886 | NNS | denotes | Studies |
T44838 | 887-899 | RB | denotes | consistently |
T54246 | 900-904 | VBP | denotes | show |
T20581 | 905-909 | IN | denotes | that |
T54967 | 910-919 | VBN | denotes | increased |
T27422 | 920-934 | NN | denotes | immunoglobulin |
T48431 | 935-941 | NNS | denotes | levels |
T7060 | 942-951 | VBP | denotes | accompany |
T92743 | 952-955 | DT | denotes | the |
T24866 | 956-966 | NN | denotes | transition |
T9522 | 967-971 | IN | denotes | from |
T69120 | 972-977 | JJ | denotes | early |
T81312 | 978-980 | TO | denotes | to |
T7048 | 981-985 | JJ | denotes | late |
T25388 | 986-992 | NN | denotes | course |
T44741 | 993-995 | IN | denotes | of |
T20679 | 996-1003 | NN | denotes | COVID19 |
T6735 | 1005-1007 | PRP | denotes | It |
T32751 | 1008-1013 | VBZ | denotes | poses |
T41840 | 1014-1017 | DT | denotes | the |
T21434 | 1018-1029 | NN | denotes | possibility |
T75450 | 1030-1034 | IN | denotes | that |
T55251 | 1035-1039 | NN | denotes | IVIG |
T48129 | 1040-1047 | NN | denotes | therapy |
T90120 | 1048-1053 | MD | denotes | might |
T91321 | 1054-1058 | VB | denotes | help |
T89890 | 1059-1061 | TO | denotes | to |
T64443 | 1062-1072 | VB | denotes | accelerate |
T5150 | 1073-1081 | NN | denotes | recovery |
T43666 | 1082-1086 | IN | denotes | from |
T85289 | 1087-1095 | NN | denotes | COVID-19 |
R37061 | T95212 | T56020 | arg1Of | Hypothesis,4.2.1 |
R21455 | T95212 | T84611 | arg1Of | Hypothesis,: |
R41659 | T50853 | T84611 | arg2Of | contains,: |
R26320 | T95417 | T50853 | arg1Of | IVIG,contains |
R55634 | T83960 | T50853 | arg2Of | pool,contains |
R11871 | T83960 | T65863 | arg1Of | pool,a |
R81126 | T83960 | T68527 | arg1Of | pool,large |
R87985 | T83960 | T57480 | arg1Of | pool,of |
R85206 | T50450 | T57480 | arg2Of | antibodies,of |
R95689 | T50450 | T98962 | arg1Of | antibodies,human |
R7397 | T12037 | T52317 | arg1Of | IVIG,is |
R59827 | T32201 | T52317 | arg2Of | treatment,is |
R45922 | T32201 | T83276 | arg1Of | treatment,an |
R32666 | T32201 | T47689 | arg1Of | treatment,immunomodulatory |
R38821 | T32201 | T26744 | arg1Of | treatment,currently |
R80185 | T26744 | T6595 | arg1Of | currently,useful |
R62385 | T6595 | T61951 | arg1Of | useful,for |
R78431 | T96672 | T61951 | arg2Of | variety,for |
R3964 | T96672 | T78252 | arg1Of | variety,a |
R72167 | T96672 | T75647 | arg1Of | variety,of |
R82814 | T37666 | T75647 | arg2Of | diseases,of |
R55274 | T37666 | T64366 | arg1Of | diseases,human |
R31515 | T37666 | T30663 | arg1Of | diseases,that |
R12726 | T37666 | T71611 | arg1Of | diseases,share |
R20851 | T35011 | T71611 | arg2Of | origin,share |
R86274 | T35011 | T4369 | arg1Of | origin,an |
R95215 | T35011 | T95969 | arg1Of | origin,idiopathic |
R10701 | T32201 | T94518 | arg1Of | treatment,"," |
R19665 | T32201 | T34533 | arg1Of | treatment,ranging |
R89530 | T34533 | T57537 | arg1Of | ranging,from |
R77337 | T10634 | T57537 | arg2Of | disorders,from |
R63281 | T10634 | T47481 | arg1Of | disorders,autoimmune |
R45693 | T34533 | T96539 | arg1Of | ranging,to |
R65268 | T91348 | T96539 | arg2Of | deficiencies,to |
R94792 | T91348 | T18270 | arg1Of | deficiencies,primary |
R91107 | T91348 | T92790 | arg1Of | deficiencies,antibody |
R9941 | T10629 | T23275 | arg1Of | shown,Also |
R28227 | T10629 | T97483 | arg1Of | shown,"," |
R92669 | T12179 | T44219 | arg1Of | IVIG,has |
R31307 | T10629 | T44219 | arg2Of | shown,has |
R77637 | T12179 | T10629 | arg1Of | IVIG,shown |
R23512 | T67208 | T10629 | arg2Of | results,shown |
R8504 | T67208 | T45168 | arg1Of | results,promising |
R20697 | T67208 | T77083 | arg1Of | results,in |
R78894 | T72909 | T77083 | arg2Of | case,in |
R82064 | T72909 | T84121 | arg1Of | case,of |
R98709 | T6178 | T84121 | arg2Of | and,of |
R28624 | T52785 | T92712 | arg1Of | and,severe |
R80380 | T52785 | T79863 | arg2Of | and,( |
R24626 | T80386 | T79863 | arg3Of | ),( |
R19944 | T43956 | T66824 | arg1Of | as,such |
R49580 | T52785 | T43956 | arg1Of | and,as |
R37840 | T13628 | T43956 | arg2Of | ",",as |
R28995 | T9832 | T13628 | arg1Of | sepsis,"," |
R16863 | T14835 | T13628 | arg2Of | infection,"," |
R40263 | T14835 | T62406 | arg1Of | infection,Parvovirus |
R95673 | T14835 | T99835 | arg1Of | infection,B19 |
R52070 | T13628 | T15497 | arg1Of | ",","," |
R13275 | T62294 | T15497 | arg2Of | encephalitis,"," |
R22619 | T76795 | T90831 | arg1Of | Nile,West |
R23224 | T62294 | T76795 | arg1Of | encephalitis,Nile |
R99263 | T62294 | T72325 | arg1Of | encephalitis,virus |
R15788 | T62294 | T79163 | arg1Of | encephalitis,"," |
R54321 | T42313 | T79163 | arg2Of | HIV,"," |
R99309 | T52785 | T73958 | arg1Of | and,"," |
R85642 | T8038 | T29310 | arg1Of | infections,Clostridium |
R55554 | T8038 | T49447 | arg1Of | infections,difficile |
R94197 | T8038 | T10219 | arg1Of | infections,"," |
R30216 | T55185 | T10219 | arg2Of | avium,"," |
R46944 | T55185 | T3443 | arg1Of | avium,Mycobacterium |
R36023 | T10219 | T2677 | arg1Of | ",","," |
R30475 | T65630 | T2677 | arg2Of | tuberculosis,"," |
R32473 | T65630 | T67405 | arg1Of | tuberculosis,Mycobacterium |
R79700 | T52785 | T60726 | arg1Of | and,"," |
R5424 | T2677 | T52785 | arg1Of | ",",and |
R82963 | T90848 | T52785 | arg2Of | infections,and |
R12367 | T90848 | T44446 | arg1Of | infections,Nocardia |
R36176 | T52785 | T6178 | arg1Of | and,and |
R5432 | T17705 | T6178 | arg2Of | infections,and |
R7624 | T17705 | T68317 | arg1Of | infections,recurrent |
R48790 | T6178 | T68999 | arg1Of | and,in |
R33893 | T62247 | T68999 | arg2Of | deficiencies,in |
R41252 | T62247 | T18422 | arg1Of | deficiencies,primary |
R34450 | T62247 | T52471 | arg1Of | deficiencies,antibodies |
R24969 | T62247 | T55724 | arg1Of | deficiencies,[ |
R29860 | T27007 | T55724 | arg2Of | 21,[ |
R45347 | T97422 | T55724 | arg3Of | ],[ |
R18045 | T48684 | T8813 | arg1Of | patients,Most |
R91845 | T48684 | T37814 | arg1Of | patients,develop |
R13100 | T41895 | T37814 | arg2Of | antibodies,develop |
R35710 | T37814 | T32237 | arg1Of | develop,against |
R20807 | T51386 | T32237 | arg2Of | and,against |
R6800 | T51386 | T55833 | arg1Of | and,the |
R22109 | T23466 | T51386 | arg1Of | NP,and |
R81797 | T97267 | T51386 | arg2Of | RBD,and |
R91140 | T51386 | T48238 | arg1Of | and,of |
R87740 | T17626 | T48238 | arg2Of | 2019-nCoV,of |
R8876 | T37814 | T87676 | arg1Of | develop,during |
R35461 | T36179 | T87676 | arg2Of | week,during |
R97441 | T36179 | T56543 | arg1Of | week,the |
R2585 | T36179 | T74019 | arg1Of | week,second |
R34363 | T37814 | T61939 | arg1Of | develop,after |
R46687 | T47949 | T61939 | arg2Of | onset,after |
R33556 | T47949 | T53819 | arg1Of | onset,infection |
R6993 | T37814 | T10621 | arg1Of | develop,[ |
R3294 | T31327 | T10621 | arg2Of | 22,[ |
R78306 | T53799 | T10621 | arg3Of | ],[ |
R98284 | T76985 | T6758 | arg1Of | Analysis,of |
R72949 | T73739 | T6758 | arg2Of | samples,of |
R94093 | T73739 | T88720 | arg1Of | samples,serum |
R64474 | T76985 | T20072 | arg1Of | Analysis,collected |
R79737 | T64515 | T20072 | arg2Of | days,collected |
R31087 | T64515 | T30704 | arg1Of | days,14 |
R58487 | T30704 | T66398 | arg1Of | 14,or |
R48701 | T30704 | T43796 | arg1Of | 14,more |
R91116 | T20072 | T88119 | arg1Of | collected,after |
R29180 | T69102 | T88119 | arg2Of | revealed,after |
R61094 | T78997 | T33297 | arg1Of | onset,symptom |
R30751 | T78997 | T69102 | arg1Of | onset,revealed |
R85646 | T51393 | T69102 | arg2Of | detection,revealed |
R94930 | T51393 | T49412 | arg1Of | detection,of |
R15007 | T84785 | T49412 | arg2Of | antibodies,of |
R35220 | T84785 | T86080 | arg1Of | antibodies,IgG |
R17029 | T86080 | T42365 | arg1Of | IgG,and |
R36223 | T24248 | T42365 | arg2Of | IgM,and |
R4871 | T84785 | T24248 | arg1Of | antibodies,IgM |
R37373 | T51393 | T33598 | arg1Of | detection,against |
R80609 | T65176 | T33598 | arg2Of | NP,against |
R29116 | T51393 | T29543 | arg1Of | detection,in |
R74727 | T54079 | T29543 | arg2Of | and,in |
R31620 | T4274 | T67075 | arg1Of | %,94 |
R41074 | T71868 | T4274 | arg1Of | %,% |
R32415 | T4274 | T73088 | arg1Of | %,and |
R53047 | T74097 | T73088 | arg2Of | 88,and |
R60224 | T71868 | T74097 | arg1Of | %,88 |
R30825 | T71868 | T54079 | arg1Of | %,and |
R92508 | T73098 | T54079 | arg2Of | RBD,and |
R99739 | T54079 | T69539 | arg1Of | and,in |
R9744 | T64615 | T69539 | arg2Of | %,in |
R73124 | T78691 | T87988 | arg1Of | %,100 |
R67370 | T64615 | T78691 | arg1Of | %,% |
R15728 | T78691 | T18580 | arg1Of | %,and |
R74845 | T46489 | T18580 | arg2Of | 94,and |
R42305 | T64615 | T46489 | arg1Of | %,94 |
R38001 | T51393 | T60810 | arg1Of | detection,among |
R89986 | T38563 | T60810 | arg2Of | patients,among |
R54593 | T38563 | T93829 | arg1Of | patients,with |
R6445 | T24980 | T93829 | arg2Of | COVID19,with |
R86911 | T54246 | T44838 | arg1Of | show,consistently |
R41127 | T89545 | T54246 | arg1Of | Studies,show |
R52555 | T7060 | T54246 | arg2Of | accompany,show |
R1890 | T7060 | T20581 | arg1Of | accompany,that |
R15150 | T48431 | T54967 | arg2Of | levels,increased |
R79272 | T48431 | T27422 | arg1Of | levels,immunoglobulin |
R9994 | T48431 | T7060 | arg1Of | levels,accompany |
R27595 | T24866 | T7060 | arg2Of | transition,accompany |
R10059 | T24866 | T92743 | arg1Of | transition,the |
R64970 | T24866 | T9522 | arg1Of | transition,from |
R11593 | T25388 | T9522 | arg2Of | course,from |
R11280 | T7048 | T69120 | arg1Of | late,early |
R61089 | T7048 | T81312 | arg1Of | late,to |
R36970 | T25388 | T7048 | arg1Of | course,late |
R76248 | T25388 | T44741 | arg1Of | course,of |
R16578 | T20679 | T44741 | arg2Of | COVID19,of |
R93295 | T6735 | T32751 | arg1Of | It,poses |
R68469 | T21434 | T32751 | arg2Of | possibility,poses |
R17888 | T21434 | T41840 | arg1Of | possibility,the |
R71902 | T91321 | T21434 | arg2Of | help,possibility |
R4510 | T91321 | T75450 | arg1Of | help,that |
R34056 | T48129 | T55251 | arg1Of | therapy,IVIG |
R30440 | T48129 | T90120 | arg1Of | therapy,might |
R46659 | T91321 | T90120 | arg2Of | help,might |
R94505 | T48129 | T91321 | arg1Of | therapy,help |
R59227 | T64443 | T91321 | arg2Of | accelerate,help |
R39248 | T64443 | T89890 | arg1Of | accelerate,to |
R27615 | T48129 | T64443 | arg1Of | therapy,accelerate |
R41612 | T5150 | T64443 | arg2Of | recovery,accelerate |
R13579 | T5150 | T43666 | arg1Of | recovery,from |
R80924 | T85289 | T43666 | arg2Of | COVID-19,from |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T135 | 231-239 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T136 | 384-387 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T137 | 695-700 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
T138 | 777-780 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T139 | 785-788 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T140 | 920-934 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T119 | 199-219 | Disease | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/MONDO_0007179 |
T120 | 223-252 | Disease | denotes | primary antibody deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
T121 | 343-352 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T122 | 364-382 | Disease | denotes | virus encephalitis | http://purl.obolibrary.org/obo/MONDO_0006009 |
T123 | 389-421 | Disease | denotes | Clostridium difficile infections | http://purl.obolibrary.org/obo/MONDO_0000705 |
T124 | 458-470 | Disease | denotes | tuberculosis | http://purl.obolibrary.org/obo/MONDO_0018076 |
T125 | 476-495 | Disease | denotes | Nocardia infections | http://purl.obolibrary.org/obo/MONDO_0017776 |
T126 | 511-524 | Disease | denotes | infections in | http://purl.obolibrary.org/obo/MONDO_0005550 |
T127 | 525-556 | Disease | denotes | primary antibodies deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
T128 | 661-670 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T129 | 870-877 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T130 | 996-1003 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T131 | 1087-1095 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T4 | 199-219 | Phenotype | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/HP_0002960 |
T5 | 320-326 | Phenotype | denotes | sepsis | http://purl.obolibrary.org/obo/HP_0100806 |
T6 | 370-382 | Phenotype | denotes | encephalitis | http://purl.obolibrary.org/obo/HP_0002383 |
T7 | 501-521 | Phenotype | denotes | recurrent infections | http://purl.obolibrary.org/obo/HP_0002719 |
T8 | 910-941 | Phenotype | denotes | increased immunoglobulin levels | http://purl.obolibrary.org/obo/HP_0010702 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T142 | 0-65 | Sentence | denotes | 4.2.1 Hypothesis: IVIG contains a large pool of human antibodies |
T143 | 66-253 | Sentence | denotes | IVIG is an immunomodulatory treatment currently useful for a variety of human diseases that share an idiopathic origin, ranging from autoimmune disorders to primary antibody deficiencies. |
T144 | 254-562 | Sentence | denotes | Also, IVIG has shown promising results in case of severe (such as sepsis, Parvovirus B19 infection, West Nile virus encephalitis, HIV, Clostridium difficile infections, Mycobacterium avium, Mycobacterium tuberculosis, and Nocardia infections) and recurrent infections in primary antibodies deficiencies [21]. |
T145 | 563-682 | Sentence | denotes | Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. |
T146 | 683-878 | Sentence | denotes | Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. |
T147 | 879-1004 | Sentence | denotes | Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. |
T148 | 1005-1096 | Sentence | denotes | It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T4 | 199-219 | Phenotype | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/HP_0002960 |
T5 | 320-326 | Phenotype | denotes | sepsis | http://purl.obolibrary.org/obo/HP_0100806 |
T6 | 370-382 | Phenotype | denotes | encephalitis | http://purl.obolibrary.org/obo/HP_0002383 |
T7 | 501-521 | Phenotype | denotes | recurrent infections | http://purl.obolibrary.org/obo/HP_0002719 |
T8 | 910-941 | Phenotype | denotes | increased immunoglobulin levels | http://purl.obolibrary.org/obo/HP_0010702 |